E-Cigarette Statistics Show Why Cannabis Stocks Are Just Getting Started

Recent data suggests that cannabis growth is just getting started. Stocks like Canopy Growth Corp (TSX:WEED)(NYSE:CGC) and Cronos Group (TSX:CRON)(NASDAQ:CRON) remain your best bets.

| More on:
edit Jars of marijuana

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

E-cigarettes are currently roiled in controversy, albeit sales growth remains positive. Looking back, it’s amazing how quickly this industry emerged.

In 2013, the global vaping market was worth just $4 billion. This year, it’s expected to approach $20 billion, which represents 500% growth in just six years.

By 2023, Euromonitor International expects the market size to surpass $45 billion. Given that the traditional cigarette market is worth around $1 trillion worldwide, decades of growth could be ahead for e-cigarettes.

Few markets are capable of this type of momentum, yet the cannabis industry looks the part. In fact, despite the hype around legalized marijuana, the data suggests that the growth has just begun.

Just getting started

The e-cigarette market shows just how quickly these markets can form and accelerate. The traditional tobacco market shows how large these markets can become over time, yet there are many cannabis-specific data points that also suggest a positive future.

In 2018, the U.S. market generated $8 billion in legal cannabis sales. Over the next several years, Cowen Inc believes that the market will grow by 30% annually, surpassing $30 billion by 2025. Several other investment banks and research firms have corroborated this projection.

Canada is expected to experience similar growth, although the country’s sales ramp is a bit ahead of its southern neighbour.

In February of this year, for example, Canadians purchased $49 million in legal pot. By June, sales had reached $85 million.

Given that the sale of popular form factors like edibles and concentrates weren’t legalized until this October, expect monthly sales to pick up considerably as 2019 comes to a close.

It’s not just industry-wide sales that are projected to rise, however. Revenue for nearly every pot stock is expected to ramp in 2020 as the market matures and consumer preferences are better aligned.

Canopy Growth Corp (TSX:WEED)(NYSE:CGC) is expected to generate US$310 million in sales this year.

Next year, however, sales are expected to more than double to US$706 million. Some analysts believe sales will grow by more than 40% annually over the next five years.

Its tie-up with Constellation Brands will surely help it capitalize on the burgeoning consumables category.

Cronos Group (TSX:CRON)(NASDAQ:CRON) is another cannabis company set for rapid growth. Analysts expect just US$38 million in revenue this year.

By the end of next year, that figure should grow to US$133 million. Tobacco behemoth Altria Group Inc, which controls half of U.S. cigarette sales, took a 45% position in the company this year.

If any stock is capable of becoming an industry giant, it’s Cronos Group, as it now has the expertise, funding, and influence of a firm with decades of success in highly-regulated markets.

The biggest sales gains, however, will be recorded by smaller competitors such as HEXO Corp. (TSX:HEXO)(NYSE:HEXO).

With a market cap of just $600 million, HEXO generated just US$36 million in sales this year. Next year, analysts expect sales to ramp to US$86 million.

By 2021, sales could approach US$200 million. With a differentiated platform approach to cannabis, this could be a long-term winner that few pot investors are paying attention to.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends Constellation Brands, HEXO., and HEXO. Fool contributor Ryan Vanzo has no position in any stocks mentioned. 

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »